Vanguard Global Advisers
IONS icon

Vanguard Global Advisers’s Ionis Pharmaceuticals IONS Stock Holding History

Vanguard Global Advisers’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.22M Sell
65,858
-6,053
-8% -$456K ﹤0.01% 778
2026
Q1 		$5.4M Buy
+71,911
New +$5.68M ﹤0.01% 744

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Global Advisers's IONS Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Ionis Pharmaceuticals (IONS) stake by 8.4% in Q2 2026, selling an estimated $456K and leaving 65,858 shares worth $5.22M. The position accounts for ﹤0.01% of the portfolio, ranked #778.

Vanguard Global Advisers first reported a position in IONS in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.4M in Q1 2026. 504 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Vanguard Global Advisers held 65,858 shares of Ionis Pharmaceuticals worth $5.22M as of Q2 2026.
  • Vanguard Global Advisers sold 6,053 Ionis Pharmaceuticals shares in Q2 2026, an estimated $456K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #778 holding.
  • Vanguard Global Advisers first reported a position in Ionis Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Ionis Pharmaceuticals position peaked at $5.4M in Q1 2026.
  • 504 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.